Detailed narrative
Transformative XOMA Royalty Acquisition
Ligand announced the acquisition of XOMA Royalty Corporation, which is expected to add over 120 commercial, clinical, and preclinical stage assets to its portfolio. This transaction is anticipated to be immediately accretive, adding $0.50 per share to adjusted EPS in 2026 and $1.50 in 2027.
The acquisition will nearly double Ligand's Phase II and Phase III assets, enhancing long-term growth and earnings potential, with some IP and royalty rights extending past 2040. The deal also brings significant tax attributes, including net operating losses and Section 174 R&D tax credits, contributing to approximately $300 million in combined operating cash flow for 2027.
Strategic Shift to Royalty Aggregation Model
Since 2022, Ligand has undergone a strategic transformation, shifting from infrastructure-heavy technology platforms to a pure royalty aggregation model. This involved divesting two platform businesses, reducing operating expenses from $90 million to $40 million, and scaling down employee count from nearly 200 to approximately 40.
The company has since added an experienced investment deal team, executing 18 deals in the last three years and growing its commercial assets from seven to 15, significantly improving profitability and operating leverage.
Filspari's Expanded Approval and Commercial Momentum
Filspari received full FDA approval for the treatment of FSGS in patients without nephrotic syndrome, expanding its label beyond IgA nephropathy. This approval is considered highly positive due to its broad label, encompassing primary, secondary, and genetic FSGS. Travere estimates over 30,000 eligible patients in the U.S. for FSGS treatment, with no approved therapeutic alternatives.
Filspari is now Ligand's largest commercial royalty asset, with Travere guiding to a $3 billion peak opportunity across both indications, translating to a potential $270 million annual royalty for Ligand.
QTORIN Rapamycin's Positive Phase III Results
Palvella's QTORIN rapamycin achieved highly statistically significant positive top-line Phase III results in microcystic lymphatic malformations (MLM), demonstrating a 2.13 point improvement on the MLM Investigator Global Assessment scale. This is clinically transformative, as there are no FDA-approved treatments for this rare dermatological condition.
Palvella plans to submit an NDA in the second half of 2026 and projects an annual per-patient price of $100,000 to $200,000, positioning the U.S. commercial opportunity for QTORIN rapamycin to reach an estimated $1 billion to $3 billion in annual sales across MLM and cutaneous venous malformations (CVM) at peak, potentially yielding $100 million to $300 million in peak annual royalty revenue for Ligand.
Robust Pipeline and Business Development Strategy
Ligand maintains a robust pipeline of targets, with a focus on single or double asset deals, though larger multi-asset opportunities like XOMA are pursued when unique. The company's deal pace is $150 million to $250 million annually, supported by strong cash flow generation approaching $300 million per year, enabling a self-funding status for new royalty opportunities.
Ligand's portfolio management capability actively farms existing assets, seeking to re-partner or finance promising programs to move them forward in development, as exemplified by the lasofoxifene asset now with LeonaBio.